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Acidic tissue microenvironment contributes to tumor progression via multiple effects
including the activation of angiogenic factors and proteases, reduced cell-cell adhesion,
increased migration and invasion, etc. In addition, intratumoral acidosis can influence the
uptake of anticancer drugs and modulate the response of tumors to conventional therapy.
Acidification of the tumor microenvironment often develops due to hypoxia-triggered
oncogenic metabolism, which leads to the extensive production of lactate, protons,
and carbon dioxide. In order to avoid intracellular accumulation of the acidic metabolic
products, which is incompatible with the survival and proliferation, tumor cells activate
molecular machinery that regulates pH by driving transmembrane inside-out and outside-in
ion fluxes. Carbonic anhydrase IX (CA IX) is a hypoxia-induced catalytic component of the
bicarbonate import arm of this machinery. Through its catalytic activity, CA IX directly
participates in many acidosis-induced features of tumor phenotype as demonstrated by
manipulating its expression and/or by in vitro mutagenesis. CA IX can function as a
survival factor protecting tumor cells from hypoxia and acidosis, as a pro-migratory factor
facilitating cell movement and invasion, as a signaling molecule transducing extracellular
signals to intracellular pathways (including major signaling and metabolic cascades) and
converting intracellular signals to extracellular effects on adhesion, proteolysis, and other
processes. These functional implications of CA IX in cancer are supported by numerous
clinical studies demonstrating the association of CA IX with various clinical correlates and
markers of aggressive tumor behavior. Although our understanding of the many faces of
CA IX is still incomplete, existing knowledge supports the view that CA IX is a biologically
and clinically relevant molecule, exploitable in anticancer strategies aimed at targeting
adaptive responses to hypoxia and/or acidosis.
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HYPOXIA AND ACIDOSIS: HAND-IN-HAND TOWARD TUMOR
PROGRESSION
During solid tumor growth, subpopulations of cancer and stro-
mal cells are exposed to variable conditions depending on the
local and temporal supply of oxygen, nutrients, growth factors
Abbreviations: AE2, anion exchanger 2; ADAM, a disintegrin and metallopro-
tease; CA IX, carbonic anhydrase protein isoform 9; CA9, human carbonic
anhydrase 9 gene; CAF, cancer-associated fibroblasts; CCRCC, clear cell renal
cell carcinoma; COX, cyclooxygenase; CREB, cAMP response element binding;
DC, dendritic cells; ECD, ectodomain; ECM, extracellular matrix; EGF, epider-
mal growth factor; EGFR, EGF receptor; EMT, epithelial-mesenchymal transition;
ER, endoplasmic reticulum; FAK, focal adhesion kinase; GIST, gastrointestinal
stromal tumor; GLUT, glucose transporter; HIF, hypoxia inducible factor; HRE,
hypoxia-response element; LDH, lactate dehydrogenase; MAPK, mitogen activated
protein kinase; MCT, monocarboxylate transporter; MMP, matrix metallopro-
teinase; MUC, mucin; NBCe1, electrogenic sodium-bicarbonate cotransporter;
NHE, sodium-hydrogen exchanger; NHERF1, Na+/H+ exchanger regulatory fac-
tor 1; PHD, prolyl hydroxylases; pHi, intracellular pH; pHe, extracellular pH;
PI3K, phosphatidyl inositol 3-kinase; PKA, protein kinase A; ROS, reactive oxygen
species; SP1, specificity protein 1; TACE, TNFα converting enzyme; TNFα, tumor
necrosis factor α; VEGF, vascular endothelial growth factor; VHL, von Hippel
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and signaling molecules by aberrant vasculature as well as on
spatial constraints imposed by the surrounding normal tissue,
elevated interstitial pressure, gradients of metabolic waste and
other factors. These physiological conditions, together with vari-
able genetic backgrounds of tumor cells caused by oncogenic
events, result in the development of highly heterogeneous tumor
tissue with a microenvironment characterized, among other fea-
tures, by regions of hypoxia and/or acidosis (Fang et al., 2008;
Gatenby and Gillies, 2008; Gillies et al., 2012).
Hypoxia is broadly studied as a biologically and clinically
important phenomenon with pronounced effects on tumor phe-
notype and cancer progression (Harris, 2002). It attracts more
and more attention, and the knowledge that has accumulated
over the past two decades is impressive (Ratcliffe, 2013). The
clear connection between hypoxia and poor prognosis as well as
the resistance to conventional treatment modalities has already
led to the implementation of modified treatment regimens and
new prognostic/predictive markers to clinical practice (Chitneni
et al., 2011; Lin and Hahn, 2012). Despite diverse manifes-
tations of hypoxia that can range from moderate to severe,
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acute to chronic, and intermittent to persistent, reduced oxygen
availability generally stimulates a distinctive set of cellular adap-
tive processes that include a shift to glycolytic metabolism, slowed
cell proliferation, diminished cell adhesion, increased migra-
tion and invasiveness, increased angiogenesis and other energy-
saving and metastasis-enabling alterations (Semenza, 2012).
These changes occur as a consequence of the massive remodeling
of the transcriptional program activated by a heterodimeric tran-
scription factor called hypoxia-inducible factor (HIF) composed
of two subunits, of which the α subunit is sensitive to oxy-
gen. Thus, HIF-α is generally missing in well-oxygenated cancer
cells due to the negative control of its stability by the PHD-
VHL pathway, although certain oncogenic events can mediate its
stabilization even under normoxic conditions. In hypoxia, PHD-
VHL effects are invalidated, HIF-α is stabilized and following
entry to the nucleus and dimerization with the constitutive HIF-
β subunit it can either turn on or elevate the transcription of a
myriad of genes containing HIF-responsive elements (HREs) in
the regulatory regions. A detailed description of the molecular
mechanisms related to isoforms of HIF-α, regulation of its sta-
bility and transactivation ability can be found in many excellent
papers (Kaelin and Ratcliffe, 2008; Lendahl et al., 2009) and will
not be discussed in this review. Here it is important to note that
proteins encoded by HIF-regulated genes (including glucose and
lactate transporters, glycolytic enzymes, pro-angiogenic growth
factors and receptors, ion transporters, etc.) execute the adaptive
responses to hypoxia and are therefore active players in tumor
progression. Moreover, some of them are clinically exploited as
hypoxia-associated biomarkers and anticancer therapy targets
(Wilson and Hay, 2011).
As mentioned above, hypoxia triggers a shift toward the gly-
colytic metabolism that allows for the sustained, albeit less effi-
cient production of energy in conditions of reduced or absent
oxygen, a substrate of oxidative phosphorylation. This is criti-
cal to the survival of hypoxic tumor cells. Hypoxia also selects
inherently glycolytic cells developed through oncogenic events.
Importantly, glycolysis not only generates energy but also facili-
tates the synthesis of biomass (e.g., nucleotides, amino acids, and
lipids) required for the production of new cells during tumor
expansion. Therefore, tumor cells rely on glycolysis even in the
presence of oxygen (Vander Heiden et al., 2009; Schulze and
Harris, 2012). Moreover, some tumor cells strongly depend on
glutaminolysis, which can feed the mitochondrial TCA cycle and
pentose phosphate pathway and thereby contribute to the syn-
thesis of fatty acids, nonessential amino acids, and nucleosides.
The excessive quantities of glutamine consumed and metabolized
by cancer cells can result in the secretion of alanine and ammo-
nium, which accumulate in the extracellular milieu (Levine and
Puzio-Kuter, 2010).
Due to an oncogenic metabolism shared to a variable extent
among respiration, glycolysis and glutaminolysis, tumor cells gen-
erate an excess of acidic metabolic products, including lactic
acid, protons, and carbon dioxide. To counteract the cytosolic
accumulation of these acidic metabolites and avoid prolonged
intracellular acidosis, cells activate constituents of the pH regulat-
ing machinery, including ion exchangers and transporters, above
the threshold of their normal activities and in some cases also
redirect the transmembrane ion fluxes compared to normal cells
(Parks et al., 2011). Many of these constituents and their regula-
tors are pH sensitive molecules and are thus activated once the
intracellular pH (pHi) reaches acidic values incompatible with
the biosynthetic reactions and signaling processes (Alper, 2006;
Odunewu and Fliegel, 2013). The purpose of their activation is
to return pHi to slightly alkaline values favorable to cell survival
and proliferation. Elimination of intracellular acidosis generally
occurs through the export of lactate and protons and through the
import of bicarbonate ions generated by the hydration of CO2 via
mechanisms that are described in more detail in the text below.
This however leads to pericellular acidosis that often persists
in tumor microenvironment because the acidic metabolic waste
cannot be effectively removed by the abnormal tumor vasculature
(Raghunand et al., 2003).
Despite being less extensively studied than tumor hypoxia
(and often remaining unappreciated as an inherent component of
hypoxia), acidosis has similarly profound effects on tumor phe-
notype. Because tumor cells can adapt, acidosis endows them
with the selective advantage against normal cells, which sup-
ports their expansion and dissemination. Thus, acidosis is asso-
ciated with clinical phenomena such as chemo/radioresistance
(Thews et al., 2006, 2010; Wojtkowiak et al., 2011), suppressed
immune/CTL responses (Fischer et al., 2000a,b; Mendler et al.,
2012), induced innate responses and inflammation (Rajamäki
et al., 2013). It also supports progression-related phenomena
such as angiogenesis (Shi et al., 2001), invasion (Martínez-
Zaguilán et al., 1996; Moellering et al., 2008; Estrella et al., 2013),
metastasis (Rofstad et al., 2006), and stemness (Hjelmeland
et al., 2011). Finally, acidosis is linked with cellular phenomena
including aneuploidy and mutation rate, autophagy and sur-
vival, cell migration, release of exosomes, etc. (Parolini et al.,
2009; Stock and Schwab, 2009; Gillies et al., 2012; Marino et al.,
2012; Wojtkowiak et al., 2012; Dai et al., 2013), see Figure 1.
Although no master HIF-like regulator has been linked with
acidosis, there are clear effects on activities of a number of
transcription factors, as detected through gene profiling studies
as well as through investigations of individual transactivators,
such as SP1, HIF-1α, CREB and others (Torigoe et al., 2003;
Mekhail et al., 2004; Shimokawa et al., 2005; Chen et al., 2008;
Peppicelli et al., 2013; Riemann et al., 2013). This suggests that
acidosis can influence the gene expression program of tumor
cells.
pH REGULATING MACHINERY: A RESCUE APPARATUS OF
HYPOXIC/ACIDIC TUMOR CELLS
Mechanisms of pH regulation in tumor cells are very complex and
intertwined with other cancer-related processes. Put simply, pH-
regulating machinery has two major arms as mentioned before:
the lactate and proton export arm, and the bicarbonate import
arm. The coordinated actions of these arms ensure that pHi is
kept at neutral or slightly alkaline values (within narrow range
of 7.2–7.4, which is similar for many tumor cell types), whereas
extracellular pH (pHe) becomes acidic (ranging more broadly
from 6.6 or even below to 6.9 in a tumor cell-related manner).
The net result of this regulation is a reversed pH gradient, which
affects ion fluxes, uptake of drugs, activation of proteases and
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FIGURE 1 | The effects of acidosis on cancer-related phenomena.
Acidosis in tumor microenvironment influences key aspects of tumor
phenotype and cancer behavior including expression reprogramming and
signal transduction (Putney and Barber, 2004; Chen et al., 2008; Riemann
et al., 2013), metabolism and survival (Parks et al., 2011; Marino et al., 2012;
Wojtkowiak et al., 2012), genomic instability (Dai et al., 2013), angiogenesis
(Shi et al., 2001; Peppicelli et al., 2013), adhesion-migration-invasion
(Martínez-Zaguilán et al., 1996; Moellering et al., 2008; Stock and Schwab,
2009; Estrella et al., 2013), metastasis and stemness (Rofstad et al., 2006;
Hjelmeland et al., 2011), aberrant immune responses (Fischer et al.,
2000a,b; Mendler et al., 2012; Rajamäki et al., 2013), and therapy resistance
(Thews et al., 2006; Wojtkowiak et al., 2011; Daniel et al., 2013).
other processes as mentioned above (Gerweck and Seetharaman,
1996; Pouysségur et al., 2006).
The export arm operates through several types of trans-
membrane ion transporters, represented in the cancer context
mainly by proton-coupled monocarboxylate transporters (MCT4
and MCT1), by Na+/H+ exchanger 1 (NHE1), and vacuo-
lar H+-APTase (Sennoune et al., 2004; Kennedy and Dewhirst,
2010; Reshkin et al., 2013). The import arm involves diverse
bicarbonate transporters, including anion exchangers (AE1-3),
electrogenic or electroneutral sodium-bicarbonate cotransporters
(NBCe1, NBCn1), and related molecules (Lauritzen et al., 2010;
Boedtkjer et al., 2013).
MCTs are 12-span transmembrane proteins encoded by the
SLC16A gene family, which can transport lactate anion across
the plasma membrane of tumor cells in association with pro-
ton (Halestrap, 2013). Of 14 MCT subtypes, only the first four
isoforms MCT1-4 transport monocarboxylates like lactate, pyru-
vate, and ketone bodies in cotransport with proton. MCT1
(SLC16A1) and MCT4 (SLC16A3) are the two isoforms most
relevant for cancer physiology. Their expression and transport
activity are closely linked with the mature form of CD147 chap-
erone and in turn, expression of MCT1 and 4 is required for
the maturation of CD147. All three molecules play active roles
in tumor biology through their growth-promoting, pro-survival,
and pro-metastatic effects (reviewed in Kennedy and Dewhirst,
2010). Both MCT1 and MCT4 can mediate lactate export as
well as import, but MCT1 has a greater affinity for lactate than
MCT4 (although the affinity of lactate in MCT4 can be increased
by exposure to lower pH values). Moreover, MCT1 is expressed
in most cells, whereas MCT4 is expressed strongly only in gly-
colytic tissues, which must export large amounts of lactic acid
(e.g., white muscle and tumors). Thus, MCT4 primarily medi-
ates lactate efflux from hyperglycolytic cells and is upregulated by
hypoxia (Ullah et al., 2006). On the other hand, MCT1 is inde-
pendent of hypoxia, activated in response to exogenous lactate,
and can equally operate in both directions, enabling the export of
intracellular lactate produced by glycolysis (in both anaerobic and
aerobic conditions) as well as the import of extracellular lactate as
a source of energy for the oxygenated cancer cells (Sonveaux et al.,
2008).
Elevated lactate has been correlated with poor disease-free,
metastasis-free and overall survival in various types of cancer
(Walenta et al., 2000; Brizel et al., 2001; Walenta and Mueller-
Klieser, 2004; Dhup et al., 2012). However, lactic acidosis in
the absence of hypoxia appears to be rather a good prognos-
tic factor in clinical breast cancer trials in contrast to hypoxia
and non-lactate acidosis, which indicate poor prognosis (Chen
et al., 2008). This is indeed compatible with the observations that
low pHe cannot be primarily attributed to lactate or its MCTs-
mediated transport and that acidification of tumor microenvi-
ronment can proceed in the absence of glycolysis as shown in
studies of glycolysis-impaired or lactate dehydrogenase-deficient
tumor cells (Newell et al., 1993; Yamagata et al., 1998; Helmlinger
et al., 2002).
NHE1 (SLC9A1) can efficiently extrude intracellular protons
in exchange for sodium ions. It is an important regulator of
both pHe and pHi in tumors and contributes to the produc-
tion and maintenance of a reverse proton gradient across the
plasma membrane of tumor cells. It also participates in the
regulatory volume increase, cytoskeletal anchoring and reorga-
nization, cell migration, invasion, and other processes associated
with tumor progression (Putney and Barber, 2004; Pedersen,
2006; Stock and Schwab, 2009). NHE1 is an 11-span integral
membrane transport protein upregulated and/or activated dur-
ing the oncogene-dependent transformation, as well as by various
growth factors and hormones, by the extracellular matrix (ECM)
receptor activation and by the physiological components of tumor
microenvironment such as low serum, acidic pHe and hypoxia
(Cardone et al., 2005; Shimoda et al., 2006; Boedtkjer et al., 2013;
Reshkin et al., 2013, for more detailed overview see Harguindey
et al., 2013). Activity of NHE1 is regulated by NHERF1 (Na+/H+
exchanger regulatory factor), a hypoxia and serum deprivation-
induced PDZ domain-containing protein, which recruits mem-
brane receptors/transporters and cytoplasmic signaling proteins
into functional complexes. Through its PDZ domain NHERF1
coordinates a protein kinase A-gated RhoA/p38/NHE1 signaling
and thereby enhances invasive phenotype of breast cancer cells
(Cardone et al., 2007).
Importantly, recent studies have shown that proton extrusion
by NHE1 represents a dynamic response to a larger acid load,
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which varies in a cell-specific manner and in most cells with high
normoxic activity it is rather inhibited by hypoxia (Hulikova et al.,
2013). Indeed, Na+/H+ exchanger is minimally active at physio-
logical pHi and most active at a very acidic pHi around 6.6 (Lee
and Tannock, 1998; Boedtkjer et al., 2013).
Thus, tumor cells dealing with a less acidic pHi close to
the physiological value (i.e., between 7.2 and 6.9) stabilize their
resting pHi at a mildly alkaline level preferentially through
bicarbonate import by a family of bicarbonate transporters,
such as Na+-coupled HCO−3 co-transporters NBCe1 (SLC4A4),
NBCn1 (SLC4A7) and Cl−/HCO−3 anion exchangers such as AE2
(SLC4A2). Accordingly, NBCe1 is most active at a pH of around
6.9 (Lee and Tannock, 1998). Moreover, the sodium-coupled
bicarbonate transport is a constitutive and stable element of pH
regulation that can effectively proceed in hypoxia (Hulikova et al.,
2013).
Bicarbonate transporters are widely distributed, expressed in
diverse isoforms and splice variants, and play important roles in
maintaining pHi as well as contributing to cell volume control,
cell migration and other cancer-related phenomena (Alper, 2006;
Boron et al., 2009).
Indeed, expression of several SLC4 family members was linked
with cancer. Particularly NBCn1 (SLC4A7) is upregulated in
breast cancer cells by ErB2/HER2 oncogene and its elevated
expression correlates with poor prognosis of patients with mam-
mary tumors (Lauritzen et al., 2010; Boedtkjer et al., 2013).
Interestingly, bicarbonate transporters can functionally substi-
tute NHE1 as demonstrated in NHE1 null mice, which induce
AE2 activity in salivary exocrine cells to rescue pHi regulation
(Gonzalez-Begne et al., 2007). Although anion exchangers are
generally viewed as acid loaders, it is imaginable that this may
change in situations where the gradient of substrate dictates an
opposite direction of transport (such as in cancer cells or in lung
erythrocytes, see Casey, 2006). In addition, pHi recovery from
intracellular acidification in the hypoxic core cells of 3D tumor
spheroids is slower upon inhibition of bicarbonate transport than
upon inhibition of Na+/H+ exchange suggesting that bicarbonate
transport is critical for coping with intracellular acidosis in tumor
cells (Hulikova et al., 2013).
However, pericellular acidosis does not permit spontaneous
formation and accumulation of bicarbonate ions as they would
immediately dissipate in the acidic extracellular milieu. In fact, it
has been shown that tumors contain less bicarbonate than normal
tissues (Stubbs et al., 1994). Thus, in the absence of a catalytic
facilitator locally producing bicarbonate ions close to the bicar-
bonate transporters, this lack of substrate would blunt or reduce
the bicarbonate import and would not allow for the activation of
this pH regulatory arm.
CA IX JOINS THE CAST
Actually, this is the situation that brings the carbonic anhydrase
IX (CA IX) to the scene. As a hypoxia-induced enzyme with an
active site facing the extracellular space and an ability to effi-
ciently catalyze the conversion of carbon dioxide to bicarbonate
ions and protons, CA IX has important prerequisites to facilitate
bicarbonate transport for the purpose of the intracellular alkalin-
ization (Pastorekova et al., 2008). It is believed that CA IX uses
its extracellular active site to catalyze CO2 hydration in a close
spatial and functional cooperation with bicarbonate transporters
(according to a so-called bicarbonate metabolon concept). The
catalysis leads to the fast local production of bicarbonate ions that
are directly delivered to bicarbonate transporters (such as NBCe1
and AE2), which bring them into the cytosol (Ditte et al., 2011;
Svastova et al., 2012). There they can take up protons to generate
CO2 that can leave the cell by diffusion and acidify the pericellular
milieu (Swietach et al., 2008). The same CO2 hydration reac-
tion catalyzed by CA IX generates also protons that remain on
the outer side of the plasma membrane and further feed acidosis
(Svastova et al., 2004). This model is supported by the experimen-
tal evidence of the in vitro interaction between the extracellular
catalytic domain of CA IX and AE2 as well as between CA IX and
NBCe1 (namely its extracellular loop 4) and also by the demon-
stration that CA IX accelerates the bicarbonate flux through
these transporters (Morgan et al., 2007; Orlowski et al., 2012).
Moreover, there is also in situ evidence obtained in living cells
by a proximity ligation assay that CA IX co-localizes and inter-
acts with bicarbonate transporters in themembranes of migrating
cells, namely in their protruding areas that are characterized by
intense ion transport (Svastova et al., 2012). Interestingly, in vitro
measurements suggest that the CO2 hydration activity of CA IX
is inhibited by an increasing concentration of bicarbonate ions
but not by lactic acid, and that the pKa optimum of CA IX is
around 6.5 (Innocenti et al., 2005, 2009). These data support
the view that this enzyme is well equipped for the acidic tumor
microenvironment.
So, depending on the angle of view and experimental
approach, CA IX can act at three interdependent points of the so-
called Jacob-Stewart cycle: it generates extracellular protons (to
decrease pHe), provides bicarbonate ions for transport and intra-
cellular consumption of protons (to increase pHi) and facilitates
CO2 diffusion (to maintain pHi>pHe gradient), see Figure 2.
Moreover, it has also been suggested that CA IX cooperates with
proton exporters by providing bicarbonate ions for taking up
a fraction of protons extruded from cells and facilitating their
extracellular mobility throughout tumor tissue (Hulikova et al.,
2012). This may be particularly important at a very low pHe,
when transmembrane bicarbonate fluxes are inhibited and bicar-
bonate ions generated by the catalytic activity of CA IX cannot
be imported to the cytoplasm. Thus, CA IX appears to spatially
coordinate ion fluxes and pH regulation in tumor tissues.
This begs the questions as to which circumstances andmolecu-
lar mechanismsmake CA IX such an important pH regulator, and
which are the situations relevant for tumor biology that involve
the enzyme activity or other molecular attributes of CA IX.
Before answering these questions, it is important to note
that CA IX is one of the 15 human isoforms of the α car-
bonic anhydrase family (Pastorek et al., 1994), members of which
are well-known players in normal physiological processes that
require intense ion transport and pH regulation in virtually all
cells/tissues of the human body. They are localized in various sub-
cellular compartments and through their catalytic activity in the
reversible hydration of carbon dioxide ranging from no/low to
high are involved in the production of gases, body fluids, bone
resorption, biosynthetic reactions etc. (Pastorekova et al., 2004).
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FIGURE 2 | Schematic illustration of the catalytic role of CA IX in pH
regulation in tumor cells. Pericellular CO2 is hydrated to bicarbonate ions
and protons in a reaction efficiently catalyzed by the hypoxia-induced CA IX.
Protons remain on the outer side of the plasma membrane and contribute
to extracellular acidification. On the other hand, CA IX-facilitated production
of bicarbonate ions is spatially and functionally coupled to their inward
transport across the plasma membrane through bicarbonate transporters
(BT) where these ions consume cytoplasmic protons and neutralize
intracellular pH. This results in production of CO2 that leaves the cell by
diffusion and may enter a new round of hydration.
With the exception of CA IX, they are all predominantly expressed
in differentiated tissues and some isoforms are also present in cer-
tain tumors, including CA II in GIST and endothelium of brain
tumors and CA XII in kidney, breast cancer etc. (Kivelä et al.,
2000; Parkkila et al., 2000, 2010; Haapasalo et al., 2008; Korhonen
et al., 2009). In contrast, CA IX is absent from the majority of
normal tissues (being abundant only in the stomach and gallblad-
der epithelia). However, it is very often and strongly expressed in
tumors, generally in their more aggressive variants and growing
clinical evidence suggests that it can serve as a prognostic indica-
tor and/or predictive factor, and a therapeutic target (reviewed in
Pastorek and Pastorekova, 2010; Oosterwijk-Wakka et al., 2013).
Thus, CA IX tissue distribution itself offers an argument that it is
actually needed in tumor cells.
REGULATION OF CA IX EXPRESSION AND FUNCTION: IS IT
ALL ABOUT HYPOXIA?
CA IX is one of the best responders to hypoxia (ranging from
anoxia to moderately reduced oxygen), in some cell types achiev-
ing several dozen or hundred-times induction. This is mainly
because the CA IX-encoding gene (according to the nomencla-
ture designated CA9) is transcriptionally regulated by hypoxia
through HIF-1 binding to an HRE sequence localized immedi-
ately in front of the transcription initiation site (Wykoff et al.,
2000). The HRE is thus a critical component of the core pro-
moter of the CA9 gene together with an adjacent SP1-binding
site. This SP1-HRE module is a principal mediator of the CA9
transcription, albeit additional cis-elements localized 5′ to the
core promoter can have modulatory effects (Kaluz et al., 2002).
SP1 appears to play a role in the induction of the CA9 tran-
scription by an increased cell density and presumably also by
an acidosis (both normoxic and hypoxic), in a cell type-specific
manner possibly depending on a threshold capacity of a given
cell type to regulate pH (Kaluz et al., 2002; Ihnatko et al., 2006).
Moreover, since expression and activation of HIF are affected by
oncogenic signaling, transcription of the CA9 gene also increases
in response to activation of the MAPK and PI3K pathways and
upstream tyrosine kinases, including SRC oncoprotein, EGFR
(epidermal growth factor receptor) and RET (Rearranged during
Transfection) oncoprotein, as well as to viral oncoproteins, such
as HBx (Kopacek et al., 2005; Holotnakova et al., 2010; Takacova
et al., 2010). Expectedly, genetic inactivation of the pVHL tumor
suppressor protein, which negatively controls HIF stability, also
results in the elevation of CA IX in kidney tumors (Ivanov et al.,
1998; Wykoff et al., 2000; Stillebroer et al., 2010).
Hypoxia also regulates the splicing of CA IX mRNA
(Barathova et al., 2008), and activates CA IX protein at the func-
tional level through the hypoxia-induced increase in cAMP levels
and activation of the protein kinase A, which phosphorylates
Thr443 in the intracellular tail of CA IX (Ditte et al., 2011).
Phosphorylation of Thr443 then mediates signaling to extracellu-
lar catalytic domain that leads to activation of the CA IX capacity
to regulate pH. CA IX is a very stable protein of about 40 h
half-life and hypoxia can induce the cleavage and release of its
ectodomain (ECD) from the cell surface to the extracellular space,
which is executed by TACE/ADAM17 that is itself regulated by
hypoxia (Rafajova et al., 2004; Zatovicova et al., 2005). The role
of the CA IX ECD remains to be elucidated. However, since all
known TACE substrates are not decoys but function as biologi-
cally active molecules, we believe that the CA IX ECD mediates
autocrine and/or paracrine intercellular signaling.
Moreover, in certain cell types and conditions, hypoxia can
induce internalization of CA IX subpopulation and its recy-
cling through the endosomal compartment (Svastova et al., 2003;
Zatovicova et al., 2010). Endocytosis is an important process
that affects stability and activity of regulatory molecules and has
many effects on signal transduction. It involves invagination of
plasma membrane regions with resident proteins and formation
of endosomes that further carry these proteins either to lysoso-
mal compartment for degradation or to recycling compartment
for their return to the cell surface. Thereby endocytosis can either
attenuate or prolong the receptor-mediated signaling (Sorkin and
von Zastrow, 2009). It remains to be elucidated whether CA IX
can signal from endosomes and whether endocytosis of CA IX is
relevant for tumor phenotype. Despite shedding and endocytosis
can reduce the plasmamembrane level of CA IX, hypoxia strongly
induces expression of new CA IX molecules, so these processes
cooperate with each other in modulation of the CA IX abundance
(explained in more detail in Zatovicova and Pastorekova, 2013).
Thus, it is quite apparent that hypoxia influences many steps in
the CA IX biogenesis, transport and functioning.
Because extracellular acidosis is an inherent component of
hypoxia that often remains unrecognized, it is difficult to discrim-
inate its contribution to each of the above-mentioned processes
regulating expression and function of CA IX. Indeed, data avail-
able in the literature show inconsistent and contradictory effects
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of acidosis on CA IX expression (Ihnatko et al., 2006; Willam
et al., 2006; Sørensen et al., 2007). Since the large genomic stud-
ies show remarkable differences in expression profiles and their
prognostic values in hypoxia, lactic acidosis, and normoxic aci-
dosis, it is very important to distinguish between these situations,
which can concurrently occur in the heterogeneous tumor tissue
(Chen et al., 2008). One possible approach toward the study of
the impact of hypoxic acidosis includes buffering of the extracel-
lular pH in hypoxic conditions. Initial data from our experiments
indicated that buffering of hypoxic acidosis leads to reduced CA
IX mRNA levels even in the cell lines that did not show marked
CA IX induction by the normoxic acidosis. This is in agreement
with the recent observation that CA IX expression in osteosar-
coma cell lines was highest in the combination of acidic (pH 6.8)
and hypoxic growth conditions (Matsubara et al., 2013).
Immunohistochemical data related to CA IX staining pat-
tern in tumor tissue clearly reflect the complex, but hypoxia-
dominating regulation of the CA IX expression. In renal cell
carcinomas, particularly of the clear cell type (CCRCC), which
often develop due to the genetic inactivation of the VHL gene,
HIF is also stabilized and activated in the absence of physiological
hypoxia (Wiesener et al., 2001). Therefore, CA IX is overexpressed
in more than 90% of these CCRCC tumors (Stillebroer et al.,
2010; Takacova et al., 2013). Expression of CA IX can be detected
in a high percentage of tumor cells and despite showing a ten-
dency to decrease at more advanced CCRCC stages, the cut-off
for positivity is 85% of cells in the tumor tissue, suggesting that
CA IX level is still very high (Bui et al., 2003). In many other
tumor types carrying the wild-type VHL gene, CA IX expression
exhibits typical focal hypoxic pattern (Wykoff et al., 2000). It is
often present in a broader perinecrotic area corresponding to the
fact that it can be transactivated already at moderate hypoxia,
mainly in the chronic setting. Thus, CA IX is also expressed
in moderately hypoxic viable tumor cells that are adaptable to
low oxygen and possess strong metastatic potential. Due to this
responsiveness to moderately reduced oxygen level, CA IX dis-
tribution only partially overlaps with the distribution of HIF-1α
as well as of additional hypoxia-induced proteins with different
hypoxic thresholds for induction (Wykoff et al., 2000; Hui et al.,
2002; Swinson et al., 2004). Sometimes, the CA IX expression
pattern is rather diffuse, possibly reflecting oncogenic alterations.
Moreover, CA IX can occasionally be found in HIF-1α-negative
areas, possibly because reoxygenation leads to degradation of
HIF-1α, but not of the highly stable CA IX protein. On the other
hand, the absence of CA IX in HIF-1α positive areas may indi-
cate increased shedding of the CA IX ectodomain. Of course,
many other factors, including microenvironmental acidosis may
influence the CA IX distribution. Indeed, acidosis can elevate the
activities of proteases, modulate cross-talk with the ECM com-
ponents, increase the release of exosomes and modulate the local
response to hypoxia (Raghunand et al., 2003; Daniel et al., 2013).
So the incomplete overlap of CA IX with HIF-1α may at least
to some extent mirror the discordant relationship between pro-
files of the partial pressure of oxygen and local pH profiles in
tumor tissue, resulting from a heterogeneity in regional pH and
pO2 distribution patterns and absence of their spatial correlation
(Helmlinger et al., 1997).
With regard to the subcellular localization, CA IX is a type
I transmembrane protein and thus it is mostly stained at the
plasma membrane of tumor cells. Although the plasma mem-
brane is the main site of residence of the mature CA IX protein
and several studies have shown its prognostic value, there are
also other compartments where CA IX can be found by immun-
odetection methods in cultured cells as well as in tumor tissues.
The cytoplasmic staining signal is often seen in tumor sections
(sometimes very strong, see Figure 3), but it is generally ignored
despite the known fact that CA IX can be endocytosed and that
cell receptors can signal not only from the cell surface but also
from endosomes (Joffre et al., 2011; Zatovicova and Pastorekova,
2013). So, the intracellular localization of CA IXmay have its bio-
logical meaning as explained above. CA IX can be also found in
the cellular components of tumor stroma (Figure 3). This stromal
signal represents either induction of endogenous CA IX in cancer-
associated fibroblasts (Fiaschi et al., 2013), or CA IX ECD released
from tumor cells and bound to the surface of immune cells or
potentially endocytosed in these cells (Wang et al., 2008). It has
actually been shown that CA IX ECD binds to the monocyte-
derived dendritic cells, so this option cannot be excluded for
other immune cell types either. Finally, in agreement with the
experimental evidence for the CA IX shedding, the CA IX ECD
can be detected in the body fluids of cancer patients (Závada
et al., 2003; Hyrsl et al., 2009; Ilie et al., 2010; Zhou et al., 2010;
Wind et al., 2011; Schütze et al., 2013). This fact can be clinically
exploited for the non-invasive screening or monitoring of cancer
patients.
CA IX ROLE IN CANCER BIOLOGY: IS IT ALL ABOUT pH
REGULATION?
CA IX expression represents a strong and frequent adaptive
response to hypoxia and/or acidosis, indicating that it is benefi-
cial for cancer cells exposed to these microenvironmental stresses.
Both experimental and clinical evidence shows that CA IX can
confer several selective advantages, particularly in situations asso-
ciated with the phenotypic consequences of a disturbed pH
homeostasis (Figure 4).
Firstly, CA IX provides a survival advantage in hypoxia and/or
acidosis. This was clearly demonstrated in several studies using
various preclinical models with genetically manipulated CA IX
expression (Chiche et al., 2009; McIntyre et al., 2012) or using
inhibitors of the CA activity (Lou et al., 2011). In all cases, CA
IX suppression, deletion of the catalytic domain, or pharmaco-
logic inhibition resulted in significantly reduced growth of tumor
xenografts. It is quite apparent that tumor cells lacking CA IX or
its enzyme activity were unable to cope with the deleterious effects
of microenvironmental stress. In support of this assumption,
shRNA silencing causing CA IX-deficiency in HT1080 tumor cells
led in decreased extracellular acidosis in hypoxia (Radvak et al.,
2013). Moreover, clinical data based on immunohistochemistry
of various tumor types show that CA IX is frequently associ-
ated with cancer progression and poor prognosis and in some
tumor tissues it is co-expressed with the markers of oncogenic
metabolism and acidosis, such as LDH5, GLUT1, MCT4 etc.
(Beasley et al., 2001; Koukourakis et al., 2006a,b; Rajaganeshan
et al., 2009; Rademakers et al., 2011; Kim et al., 2013).
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FIGURE 3 | Distribution of CA IX in the tumor tissue specimen from
CCRCC patients. Immunohistochemical staining pattern of CA IX shows
positive staining signal predominantly localized in the plasma membranes
(A), but also in cytoplasm (B), and perinuclear regions (arrows, A, B) of the
tumor cells. Moreover, CA IX can be detected in the stromal cells (C).
Tissue processing and staining procedures were as described in Takacova
et al. (2013). Briefly, dissected tissues were embedded in paraffin according
to the standard histological procedure and sectioned.
Immunohistochemistry was performed on an automated immunostainer
(Dako) using M75 antibody (hybridoma medium diluted 1:100) and
DakoCytomation Envision® + System-HRP according to the manufacturer’s
instructions. Staining was visualized with DAB solution for 1min with
3,3′-diaminobenzidine as a chromogenic substrate. Finally, the stained
sections were counterstained with Mayer’s hematoxylin, mounted, and
examined.
Secondly, CA IX appears to confer resistance to therapy,
including chemotherapy, radiotherapy, and anti-angiogenic treat-
ment. The preclinical evidence again comes from the studies
of animals xenografted with human tumor cells differing in
expression of CA IX and treated with radiation or various drugs
(chemotherapeutic agents and CA inhibitors). Tumors with a
high CA IX level were less responsive to experimental therapy, but
inhibition of CA IX catalytic activity significantly improved their
chemo- or radiosensitivity (Dubois et al., 2011, 2013). Similarly,
CA IX inhibition enhanced the effect of anti-angiogenic therapy
with anti-VEGF antibody (McIntyre et al., 2012). These findings
suggests that the pH regulatory function of CA IX is important
for the protection of tumor cells from the toxic effects of drugs
or radiation, in agreement with the concept that extracellular
acidosis may negatively affect drug uptake and radiation dam-
age (Wojtkowiak et al., 2011). There are also many clinical data
demonstrating the correlation between CA IX expression and
poor therapy outcome in cancer patients (Giatromanolaki et al.,
2001; Span et al., 2003; Koukourakis et al., 2006a,b, 2008; Korkeila
et al., 2009; Tan et al., 2009).
CA IX also facilitates the migration and invasion of tumor
cells through participation in pH regulating apparatus of the
lamellipodial membranes at the protruding fronts of moving cells
(Svastova et al., 2012). Migration and invasion are the initial steps
of the metastatic cascade that can be stimulated by hypoxia as
well as by extracellular acidosis, which activates growth factors
and extracellular matrix-degrading proteases. The ability of cells
to migrate strongly depends on the establishment of the correct
pH gradients along the longitudinal cell axis, with acidic pHe and
alkaline pHi at the cell front, and alkaline pHe and acidic pHi
at the cell rear (Stock and Schwab, 2009; Martin et al., 2011).
This is connected with the accumulation of an array of ion trans-
porters and pumps in the lamellipodial membranes accomplished
through a directed vesicular transport that includes endocyto-
sis and recycling (Schwab et al., 2012). CA IX is also relocalized
to the lamellipodia of migrating cells (see Figure 5), where it
was shown to interact with bicarbonate transporters in order to
facilitate bicarbonate import and maintain optimal pH gradi-
ent as discussed in more detail elsewhere (Svastova et al., 2012;
Svastova and Pastorekova, 2013). Importantly, this function of CA
IX requires intact catalytic domain suggesting that it is related to
pH regulation. Moreover, CA IX participates in the formation of
nascent adhesion contacts at the leading edge of migrating cells,
where these dynamic structures mediate transmission of large
forces during the forward movement of the cell body (Csaderova
et al., 2013).
In addition, CA IX contributes to the assembly andmaturation
of focal adhesion contacts during initial cell spreading (Csaderova
et al., 2013), Figure 5. Interestingly, cells expressing the truncated
form of CA IX lacking the N-terminal PG-domain as well as the
cells expressing the full length CA IX protein and treated with the
PG domain-bindingM75 antibody display a significantly reduced
spreading (Csaderova et al., 2013). The PG domain exhibits an
amino-acid sequence homology to proteoglycans and is absent
from the other CA isoenzymes (Opavský et al., 1996). Although
in vitromeasurements indicate that the PG domain can stimulate
the catalytic activity of CA IX, its deletion did not affect the abil-
ity of CA IX to acidify extracellular medium in hypoxic MDCK
cells (Svastova et al., 2004; Innocenti et al., 2009). Thus, it is dif-
ficult to judge whether or not the CA IX role in cell spreading is
related to its pH regulating function and more experimentation
is needed to come to a reliable conclusion. Moreover, while pH
nanodomains were recognized in lamellipodial focal adhesions of
migrating cells (Ludwig et al., 2013), no such phenomenon has so
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FIGURE 4 | The functional contribution of CA IX to the cancer-related
phenomena affected by acidosis in tumor microenvironment. CA IX
appears to be involved in many aspects of tumor progression as supported by
the experimental evidence in preclinical models as well as by the clinical data
from tumor tissue specimens. CA IX induces changes in activities and/or
levels of kinases, ion transporters and other regulatory molecules and its
expression correlates with certain cancer markers (Giatromanolaki et al.,
2001; Bartosova et al., 2002; Swinson et al., 2004; Dorai et al., 2005;
Skrzypski et al., 2008; Shin et al., 2011; Csaderova et al., 2013; Radvak et al.,
2013), CA IX protects tumor cells from hypoxia and acidosis and its
expression correlates with poor disease-free survival (DFS), overall survival
(OS) and markers of tumor hypoxia and metabolism (Beasley et al., 2001;
Koukourakis et al., 2006a,b; Chiche et al., 2009; Rajaganeshan et al., 2009;
Lou et al., 2011; Rademakers et al., 2011; McIntyre et al., 2012; Kim et al.,
2013). Although its direct role in genomic instability and angiogenesis has not
been analyzed (N.A.), CA IX modulates expression of EMC components
including MMP2, MMP9 and collagen IV (Radvak et al., 2013) and its
expression correlates with loss of heterozygozity (LOH) in head and neck
carcinoma (De Schutter et al., 2006) and with microvascular density
(Couvelard et al., 2005a,b). CA IX also reduces cell-cell adhesion, increases
migration and invasion of tumor cells (Svastova et al., 2003; Sansone et al.,
2009; Svastova et al., 2012) and its expression and distribution correlates with
invasive tumor phenotype (Chen et al., 2005; Rajaganeshan et al., 2009;
Deschamps et al., 2012);. CA IX also promotes stemness and correlates with
higher histological grades and metastatic disease (Sansone et al., 2007a,b;
Storci et al., 2008; Chen et al., 2010; Currie et al., 2013; Fujiwara et al., 2013;
Lock et al., 2013). CA IX induces pro-inflammatory phenotype and participates
in communication between cancer cells and stroma (Sansone et al., 2009;
Fiaschi et al., 2013). It is associated with increased resistance to conventional
therapy and its expression correlates with poor therapy outcome (Tomes
et al., 2003; Cleven et al., 2007; Brockton et al., 2011, 2012; Guedj et al.,
2011; Kwon et al., 2013).
FIGURE 5 | CA IX localization in the spreading cells (A,B) and in the
lamellipodium of the migrating cell (C). Immunofluorescence staining of
hypoxic SiHa cells attaching to the collagen support shows that CA IX is
recruited (A) to filopodia and to emerging focal contacts in the early stage of
spreading (10min after seeding) and (B) to maturing focal adhesions in the
later stage (20min after seeding). SiHa cells incubated in hypoxia for 48 h and
stimulated to migration by hepatocyte growth factor for 2 h exhibit the CA IX
signal concentrated on the protruding cell front, in the plasma membrane of
the lamellipodium (C). The CA IX staining was performed using M75
monoclonal antibody followed by anti-mouse IgG conjugated with Alexa
Fluor 488 and the nuclei were stained with DAPI as described in Svastova
et al. (2012) and Csaderova et al. (2013).
far been described for focal adhesion contacts of spreading cells,
urging further investigations in this direction.
CA IX also appears to be involved in the destabilization of
cell-cell adhesion contacts, which is the first prerequisite for
the detachment of cells from the tumor tissue and their mor-
phological remodeling toward themigration-pronemesenchymal
phenotype (Svastova et al., 2003). The underlying mechanism
includes the CA IX-mediated disconnection of E-cadherin from
the cytoskeletal anchorage through the competitive binding to
beta catenin (Svastova et al., 2003). Again, it is not clear whether
this propensity of CA IX relates to its pH regulating func-
tion. In fact, there are almost no data related to pH effects on
E-cadherin expression and/or its function during tumor pro-
gression. However, acidosis in the synaptic cleft reduced the
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N-cadherin-mediated adhesion and facilitated synaptic remodel-
ing (Baumgartner et al., 2013), so it is imaginable that a similar
situation in tumor tissue may influence adhesion between tumor
cells.
Experimental evidence for the role of CA IX in cell migra-
tion and invasion includes the CA IX suppression in HT1080
cells leading to reduced spreading and migration (Radvak et al.,
2013), CA IX suppression in colorectal carcinoma cells leading to
reduced invasion capacity in a COX-2 related manner (Sansone
et al., 2009), as well as the pharmacologic inhibition of CA IX
in mice xenografted with breast cancer cells leading to reduced
growth of metastases (Gieling et al., 2012). There are also a num-
ber of clinical studies showing the correlation between the CA IX
expression and invasive phenotype (with CA IX localized at the
invasive front) or metastatic propensity (Chen et al., 2005, 2010;
Kon-no et al., 2006; Rajaganeshan et al., 2009).
Increased expression of CA IX at advanced stages/grades of
many tumor types also suggests its association with dediffer-
entiation. Hypoxia is one of the driving forces of cancer cell
dedifferentiation toward the stem cell-like phenotype (Axelson
et al., 2005). This phenotypic remodeling occurs through upreg-
ulation of molecules contributing to stemness and CA IX appears
to be involved in this phenomenon (Sansone et al., 2007a,b; Storci
et al., 2008; Fujiwara et al., 2013). Its expression correlates with
the expression of a stem cell marker CD44 in breast carcinomas
(Chen et al., 2010; Currie et al., 2013; Fujiwara et al., 2013) and
its targeting results in the inhibition of breast cancer stem cell
expansion in hypoxia (Lock et al., 2013). Since the depletion of
breast cancer stem cells was observed upon the inhibition of the
CA IX catalytic activity, we may propose that the pH-regulating
function of CA IX is required for the maintenance of stemness.
This is indeed the indication of the importance of pH regulation
for cancer stem cell phenotype, in line with the data from litera-
ture relating extracellular acidosis to the promotion of stemness
(Hjelmeland et al., 2011).
Finally, CA IX appears to be involved in communication
between tumor cells and cellular components of the stroma. It
has recently been demonstrated that CA IX expression can be
induced in cancer-associated fibroblasts (CAFs) in response to
ROS-mediated stabilization of HIF-1 in normoxia and that up-
regulation of CA IX in CAFs leads to extracellular acidosis and
activation of EMT in epithelial cancer cells. Importantly, the
silencing of CA IX in CAFs is sufficient to prevent lung metas-
tasis from co-injected prostate cancer cells in vivo, suggesting its
crucial role in cancer progression (Fiaschi et al., 2013). In addi-
tion, earlier studies suggest that CA IX ectodomain can mediate
paracrine signaling via binding to the surface of dendritic cells
(DC) and potentially modulate their immune responses (Wang
et al., 2008). This might be particularly interesting in light of the
fact that hypoxia promotes recruitment and pro-inflammatory
phenotype in DCs within tumor tissue (Bosco and Varesio, 2012).
Again, clinical evidence from human tumors shows that stromal
CA IX expression is strongly associated with the poor survival of
head and neck cancer patients as well as in patients with colorec-
tal cancer (Tomes et al., 2003; Cleven et al., 2007; Brockton et al.,
2011, 2012; Kwon et al., 2013), and that in colorectal carcinoma,
CA IX is co-expressed with the pro-inflammatory enzyme COX-2
(Sansone et al., 2009).
However, CA IX is not only an enzyme involved in pH control,
but also a regulatory molecule involved in signal transduction.
There are several studies exploiting mutagenesis or manipu-
lated expression approaches, which link CA IX to major signal
transduction pathways. These studies show that EGF-stimulated
phosphorylation of Tyr449 of CA IX leads to the activation
of PI3K/Akt pathway (Dorai et al., 2005), that Thr443 of CA
IX transmits signals from the hypoxia activated PKA to stimu-
late bicarbonate production coupled with import (Ditte et al.,
2011), that overexpression of CA IX promotes the activation
of FAK/PI3K/mTOR/p70S6K pathway (Shin et al., 2011), and
that CA IX deficiency reduces the activity of ROCK1 and affects
expression of many migration-related genes including MMP2
and MMP9 (Csaderova et al., 2013; Radvak et al., 2013). These
signaling events then lead to the phenotypic effects described
above. Nevertheless, many other molecules, which transcrip-
tionally respond to changes in CA IX levels, are listed in the
microarray datasheets and their further investigation will surely
shed more light on the position of CA IX in the signal trans-
duction network. Immunohistochemical studies of various tumor
tissues revealed that CA IX is co-expressed with diverse signaling
molecules, including EGFR, MUC-1, cErb22, CD44, VEGF, etc.
and at least in some cases this may suggest cross-talk between
the pathways related to these molecules (Giatromanolaki et al.,
2001; Bartosova et al., 2002; Swinson et al., 2004; Skrzypski et al.,
2008).
CONCLUSION
The data summarized in this overview clearly show that CA IX
is functionally relevant for tumor phenotype particularly in con-
nection with hypoxia and acidosis and that its biological role
can be mainly attributed to pH regulation. In addition, there
are certain situations, in which CA IX appears to act through
the structural domains outside of the catalytic site and these
actions appear to be pH-independent, at least at the first glance.
However, many cellular processes have not been explored in detail
in relation to pH nano- or microenvironments present in the
subcellular compartments and to pH nano- or microdomains
of the plasma membrane regions responding to various extra-
cellular and intracellular stimuli (cell spreading, dissociation
of cell-cell contacts, intracellular signaling, ectodomain signal-
ing etc.). Thus, additional investigations are needed to eluci-
date whether these seemingly pH-unrelated features of CA IX
are involved in cellular adaptations to dynamic pH perturba-
tions or whether they contribute to different aspects of tumor
biology.
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